Crossignal Therapeutics
A clinical-stage biotechnology company focused on discovery and development of small-molecule immuno-oncology therapeutics that target tumor microenvironment‑expressed GPCRs (referred to as TMERs). The company pursues target identification, immune cell expression profiling, pathway elucidation, assay development, medicinal chemistry and early clinical development (Phase 1/2a) of candidates that modulate tumor immune escape pathways such as Hippo‑YAP and adenosine signaling.
Industries
Nr. of Employees
small (1-50)
Crossignal Therapeutics
505 Coast Blvd. S. Ste. 406, La Jolla, CA 92037, US
Patents
Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists
US-12065444-B2
View Details
Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists
US-12065444-B2
View DetailsProducts
CT3001
A small‑molecule inhibitor targeting GPR35 (a TMER) designed to modulate Hippo‑YAP signaling and block IDO1‑mediated tumor immune escape; developed for GPR35+ IDO1+ solid tumors.
CT3021
A small‑molecule, highly potent triple antagonist of adenosine receptors (A2a, A2b, A1) developed for tumors with adenosine pathway activity; reported in IND‑enabling stage.
TMER3‑i
Discovery‑stage small‑molecule program against an undisclosed TMER aimed at modulating Hippo‑YAP to block tumor immune escape; at candidate nomination stage.
TMER4‑i
Early discovery small‑molecule program against an undisclosed TMER focused on Hippo‑YAP regulation; in hit‑to‑lead progression.
Small‑molecule PD‑1/PD‑L1 blocker (discovery)
Discovery‑stage small‑molecule program aimed at blocking PD‑1/PD‑L1 interaction for mono or combination immuno‑oncology use; currently in hit‑to‑lead stage.
CT3001
A small‑molecule inhibitor targeting GPR35 (a TMER) designed to modulate Hippo‑YAP signaling and block IDO1‑mediated tumor immune escape; developed for GPR35+ IDO1+ solid tumors.
CT3021
A small‑molecule, highly potent triple antagonist of adenosine receptors (A2a, A2b, A1) developed for tumors with adenosine pathway activity; reported in IND‑enabling stage.
TMER3‑i
Discovery‑stage small‑molecule program against an undisclosed TMER aimed at modulating Hippo‑YAP to block tumor immune escape; at candidate nomination stage.
TMER4‑i
Early discovery small‑molecule program against an undisclosed TMER focused on Hippo‑YAP regulation; in hit‑to‑lead progression.
Small‑molecule PD‑1/PD‑L1 blocker (discovery)
Discovery‑stage small‑molecule program aimed at blocking PD‑1/PD‑L1 interaction for mono or combination immuno‑oncology use; currently in hit‑to‑lead stage.
Expertise Areas
- Immuno‑oncology small‑molecule drug discovery
- GPCR target identification and validation
- Assay development for pathway‑focused GPCR screening
- Medicinal chemistry and SAR optimization
Key Technologies
- Small‑molecule therapeutics
- GPCR targeting
- Pathway‑precision screening assays
- Structure‑activity relationship (SAR) studies
News & Updates
Company announced first‑in‑patient dosing for CT3001, a first‑in‑class small‑molecule GPR35‑YAP inhibitor indicated for solid tumors.
Poster titled evidence for a role of GPR35 in IDO1‑mediated tumor immune escape by regulating Hippo‑YAP pathway presented at AACR Annual Meeting 2024.
Poster presenting discovery of CT3021, a potent adenosine A2a/A2b/A1 receptor triple antagonist, at AACR Annual Meeting 2024.
Received industry recognition from a trade publication for immunotherapy solutions providers (cover story feature).
Received IND clearance from the U.S. Food and Drug Administration for the GPR35 (TMER1) inhibitor CT3001 to enter clinical phase.
Company announced first‑in‑patient dosing for CT3001, a first‑in‑class small‑molecule GPR35‑YAP inhibitor indicated for solid tumors.
Poster titled evidence for a role of GPR35 in IDO1‑mediated tumor immune escape by regulating Hippo‑YAP pathway presented at AACR Annual Meeting 2024.
Poster presenting discovery of CT3021, a potent adenosine A2a/A2b/A1 receptor triple antagonist, at AACR Annual Meeting 2024.
Received industry recognition from a trade publication for immunotherapy solutions providers (cover story feature).
Received IND clearance from the U.S. Food and Drug Administration for the GPR35 (TMER1) inhibitor CT3001 to enter clinical phase.